AU2016415408B2 - Rotigotine behenate, and preparation method and use thereof - Google Patents

Rotigotine behenate, and preparation method and use thereof Download PDF

Info

Publication number
AU2016415408B2
AU2016415408B2 AU2016415408A AU2016415408A AU2016415408B2 AU 2016415408 B2 AU2016415408 B2 AU 2016415408B2 AU 2016415408 A AU2016415408 A AU 2016415408A AU 2016415408 A AU2016415408 A AU 2016415408A AU 2016415408 B2 AU2016415408 B2 AU 2016415408B2
Authority
AU
Australia
Prior art keywords
rotigotine
crystal form
behenate
rotigotine behenate
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016415408A
Other languages
English (en)
Other versions
AU2016415408A1 (en
Inventor
Yongtao JIANG
Ying MENG
Chunjie SHA
Xin SHAO
Tao Wang
Qian qian XU
Mina Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geneora Pharma Shijiazhuang Co Ltd
Original Assignee
Geneora Pharma Shijiazhuang Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geneora Pharma Shijiazhuang Co Ltd filed Critical Geneora Pharma Shijiazhuang Co Ltd
Publication of AU2016415408A1 publication Critical patent/AU2016415408A1/en
Application granted granted Critical
Publication of AU2016415408B2 publication Critical patent/AU2016415408B2/en
Assigned to GENEORA PHARMA (SHIJIAZHUANG) CO., LTD. reassignment GENEORA PHARMA (SHIJIAZHUANG) CO., LTD. Request for Assignment Assignors: SHANDONG LUYE PHARMACEUTICAL CO., LTD.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/08—Hydrogen atoms or radicals containing only hydrogen and carbon atoms
    • C07D333/10—Thiophene
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
AU2016415408A 2016-07-21 2016-07-21 Rotigotine behenate, and preparation method and use thereof Active AU2016415408B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/090803 WO2018014277A1 (zh) 2016-07-21 2016-07-21 罗替戈汀山嵛酸酯及其制备方法和用途

Publications (2)

Publication Number Publication Date
AU2016415408A1 AU2016415408A1 (en) 2019-01-17
AU2016415408B2 true AU2016415408B2 (en) 2019-04-11

Family

ID=60992805

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016415408A Active AU2016415408B2 (en) 2016-07-21 2016-07-21 Rotigotine behenate, and preparation method and use thereof

Country Status (15)

Country Link
US (2) US10669249B2 (https=)
EP (1) EP3489227B1 (https=)
JP (1) JP6751208B2 (https=)
KR (1) KR20190031314A (https=)
CN (1) CN109415335B (https=)
AU (1) AU2016415408B2 (https=)
BR (1) BR112019001035A2 (https=)
CA (1) CA3030043C (https=)
ES (1) ES2855976T3 (https=)
MY (1) MY195897A (https=)
PH (1) PH12018550212A1 (https=)
PL (1) PL3489227T3 (https=)
RU (1) RU2717542C9 (https=)
SG (1) SG11201811543XA (https=)
WO (1) WO2018014277A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение
CN108341798B (zh) * 2017-01-23 2021-05-25 沈阳药科大学 罗替戈汀衍生物及其制备和应用
CN114423746A (zh) * 2019-09-30 2022-04-29 山东绿叶制药有限公司 化合物及其制备方法和用途
JP7621009B2 (ja) * 2020-10-27 2025-01-24 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 テトラヒドロナフタレン系化合物、その医薬組成物及びその使用
WO2024208226A1 (zh) * 2023-04-04 2024-10-10 广州市恒诺康医药科技有限公司 四氢萘类化合物、其药物组合物及其用途
CN119504742B (zh) * 2024-11-18 2025-10-28 陕西师范大学 一种娃儿藤碱和安托芬的全合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168033A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239196T3 (es) * 2002-12-02 2005-09-16 Schwarz Pharma Ag Suministro iontoforetico de rotigotina para el tratamiento de la enfermedad de parkinson.
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
KR101481643B1 (ko) 2010-11-25 2015-01-12 산동 루예 파마슈티칼 컴파니 리미티드 로티고틴, 이의 유도체 또는 로티고틴 또는 이의 유도체의 약제학적으로 허용가능한 염의 조성물
US9956201B2 (en) * 2014-07-21 2018-05-01 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy N-substituted-2-aminotetralins, and related dosage forms
RU2717542C9 (ru) * 2016-07-21 2020-08-12 Шаньдун Луе Фармасьютикал Ко., Лтд. Ротиготина бегенат, его способ получения и применение

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013168033A1 (en) * 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
WO2016014242A1 (en) * 2014-07-21 2016-01-28 Spriaso Llc Compositions comprising bioreversible derivatives of hydroxy n-substituted-2-aminotetralins, dosage forms, and related methods

Also Published As

Publication number Publication date
BR112019001035A2 (pt) 2019-04-30
PL3489227T3 (pl) 2021-05-04
JP2019523297A (ja) 2019-08-22
MY195897A (en) 2023-02-27
US20200255396A1 (en) 2020-08-13
RU2717542C1 (ru) 2020-03-24
PH12018550212A1 (en) 2019-10-28
EP3489227B1 (en) 2020-10-21
US10669249B2 (en) 2020-06-02
CN109415335A (zh) 2019-03-01
AU2016415408A1 (en) 2019-01-17
CA3030043C (en) 2021-01-19
JP6751208B2 (ja) 2020-09-02
SG11201811543XA (en) 2019-02-27
WO2018014277A1 (zh) 2018-01-25
CN109415335B (zh) 2020-06-05
US20190330177A1 (en) 2019-10-31
EP3489227A4 (en) 2020-01-22
ES2855976T3 (es) 2021-09-27
EP3489227A1 (en) 2019-05-29
US11111227B2 (en) 2021-09-07
RU2717542C9 (ru) 2020-08-12
CA3030043A1 (en) 2018-01-25
KR20190031314A (ko) 2019-03-25

Similar Documents

Publication Publication Date Title
US11111227B2 (en) Rotigotine behenate, and manufacturing method and application thereof
EP2310363B1 (en) Anticancer oral formulation
EP3248983B1 (en) Crystal form a of obeticholic acid and preparation method therefor
JP2019523297A5 (https=)
JP2015508408A (ja) プロスタグランジン類似体の結晶型およびその製造方法と用途
JP7421804B2 (ja) ブプレノルフィン誘導体の長時間作用性注射製剤および結晶形
AU2018251119A1 (en) Opioid receptor (MOR) agonist salt, fumarate salt I crystal form thereof and preparation method thereof
JP2021169501A (ja) オキシステロールの多型およびそれらの製造方法
CN108727347B (zh) 一种阿片样物质受体(mor)激动剂的晶型及其制备方法
WO2021047406A1 (zh) 一种三并环类化合物，包含其的药物组合物，其制备方法及其用途
CN116768909B (zh) Vanin酶抑制剂的盐型、晶型及其制备方法和应用
CN104650109B (zh) 紫杉烷类化合物
WO2024188169A1 (zh) 别孕烷醇酮衍生物的盐型、多晶型及其制备方法和用途
JP6522094B2 (ja) ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
CN117843578A (zh) 硒酯类化合物及其制备方法和在医药上的用途
AU2014371150A1 (en) Crystals (2) of pyrazino[2,1-c][1,2,4]triazine compound
WO2018214877A1 (zh) 一种地佐辛晶型及其制备方法
TW202245793A (zh) 3-羥基-5-孕烷-20-酮衍生物的晶型及其製備方法和用途
HK40004499A (en) Rotigotine behenate, and manufacturing method and application thereof
HK40004499B (en) Rotigotine behenate, and manufacturing method and application thereof
CN107540589A (zh) 一种艾尔骨化醇晶型、药物组合物及制备方法和应用
WO2015074605A1 (zh) 一种紫杉烷类化合物、其制备方法和用途
JP2022551176A (ja) 置換窒素複素環化合物およびその麻酔作用
RU2779119C2 (ru) Соль агониста опиоидного рецептора (mor), кристаллическая форма i его фумаратной соли и способ их получения
WO2017076358A1 (zh) 咪唑基联苯基化合物盐的新晶型及其制备方法

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ ROTIGOTINE BEHENATE, AND PREPARATION METHOD AND USE THEREOF

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: GENEORA PHARMA (SHIJIAZHUANG) CO., LTD.

Free format text: FORMER OWNER(S): SHANDONG LUYE PHARMACEUTICAL CO., LTD.